Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Channick

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 7, 2026
Methamphetamine-associated PAH on the Rise in the US: Geographic Trends & Disparities in Patient Demographics and Treatment StrategiesNick H Kim, Vinicio de Jesus Perez, John Kingrey, et al.
American Journal of Respiratory and Critical Care Medicine|February 28, 2019
Perfusion Imaging Distinguishes Exercise Pulmonary Arterial Hypertension at RestPuja Kohli, Vanessa J Kelly, Ekaterina G Kehl, et al.
Pulmonary Circulation|November 16, 2022
Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)Vallerie V McLaughlin, Richard Channick, Nick H Kim, et al.
JHLT Open|March 27, 2025
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertensionRichard Channick, Sarah Medrek, Marion Delcroix, et al.
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
The European Respiratory Journal|August 19, 2017
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertensionSean Gaine, Kelly Chin, Gerry Coghlan, et al.
Advances in Therapy|November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label ExtensionNazzareno Galiè, Sean Gaine, Richard Channick, et al.
Arthritis and Rheumatism|September 12, 2013
Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertensionDinesh Khanna, Heather Gladue, Richard Channick, et al.
Journal of the American College of Cardiology|June 25, 2003
Beraprost therapy for pulmonary arterial hypertensionRobyn J Barst, Michael McGoon, Vallerie McLaughlin, et al.
Circulation|April 16, 2019
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial HypertensionKelly M Chin, Lewis J Rubin, Richard Channick, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 7, 2026
Methamphetamine-associated PAH on the Rise in the US: Geographic Trends & Disparities in Patient Demographics and Treatment StrategiesNick H Kim, Vinicio de Jesus Perez, John Kingrey, et al.
American Journal of Respiratory and Critical Care Medicine|February 28, 2019
Perfusion Imaging Distinguishes Exercise Pulmonary Arterial Hypertension at RestPuja Kohli, Vanessa J Kelly, Ekaterina G Kehl, et al.
Pulmonary Circulation|November 16, 2022
Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)Vallerie V McLaughlin, Richard Channick, Nick H Kim, et al.
JHLT Open|March 27, 2025
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertensionRichard Channick, Sarah Medrek, Marion Delcroix, et al.
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
The European Respiratory Journal|August 19, 2017
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertensionSean Gaine, Kelly Chin, Gerry Coghlan, et al.
Advances in Therapy|November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label ExtensionNazzareno Galiè, Sean Gaine, Richard Channick, et al.
Arthritis and Rheumatism|September 12, 2013
Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertensionDinesh Khanna, Heather Gladue, Richard Channick, et al.
Journal of the American College of Cardiology|June 25, 2003
Beraprost therapy for pulmonary arterial hypertensionRobyn J Barst, Michael McGoon, Vallerie McLaughlin, et al.
Circulation|April 16, 2019
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial HypertensionKelly M Chin, Lewis J Rubin, Richard Channick, et al.
Pageof 8